These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35165399)

  • 1. PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.
    Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Ren ZL; Zhang JJ; Liu SW; Yu L; Li YL
    Acta Pharmacol Sin; 2022 Sep; 43(9):2397-2409. PubMed ID: 35165399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
    Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
    PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unconventional mechanism of action and resistance to rapalogs in renal cancer.
    Yang J; Butti R; Cohn S; Toffessi-Tcheuyap V; Mal A; Nguyen M; Stevens C; Christie A; Mishra A; Ma Y; Kim J; Abraham R; Kapur P; Hammer RE; Brugarolas J
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2310793121. PubMed ID: 38861592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
    Vlachostergios PJ; Papathanassiou M; Anagnostou M; Thodou E; Tamposis I; Mitrakas L; Zachos I; Koukoulis GK; Samara M; Tzortzis V
    F1000Res; 2023; 12():918. PubMed ID: 38933491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
    Nassar AH; Hamieh L; Gray KP; Thorner AR; Fay AP; Lasseter KD; Abou Alaiwi S; Nuzzo PV; Flippot R; Krajewski KM; Signoretti S; Choueiri TK; Kwiatkowski DJ
    Mol Cancer Ther; 2020 Feb; 19(2):690-696. PubMed ID: 31653662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
    Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of clear-cell renal cell carcinoma.
    Brugarolas J
    J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
    Xu J; Pham CG; Albanese SK; Dong Y; Oyama T; Lee CH; Rodrik-Outmezguine V; Yao Z; Han S; Chen D; Parton DL; Chodera JD; Rosen N; Cheng EH; Hsieh JJ
    J Clin Invest; 2016 Sep; 126(9):3526-40. PubMed ID: 27482884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
    Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
    Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.
    Feng C; Sun Y; Ding G; Wu Z; Jiang H; Wang L; Ding Q; Wen H
    Sci Rep; 2015 Apr; 5():9465. PubMed ID: 25853938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
    Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
    J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
    Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN Expression, Not Mutation Status in
    Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
    Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
    Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
    Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
    Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
    Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.